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Abstract: The molecular mechanisms involved in human aging are complicated. Two progeria 
syndromes, Werner’s syndrome (WS) and Hutchinson-Gilford progeria syndrome (HGPS), 
characterized by clinical features mimicking physiological aging at an early age, provide 
insights into the mechanisms of natural aging. Based on recent ﬁ  ndings on WS and HGPS, 
we suggest a model of human aging. Human aging can be triggered by two main mechanisms, 
telomere shortening and DNA damage. In telomere-dependent aging, telomere shortening and 
dysfunction may lead to DNA damage responses which induce cellular senescence. In DNA 
damage-initiated aging, DNA damage accumulates, along with DNA repair deﬁ  ciencies, result-
ing in genomic instability and accelerated cellular senescence. In addition, aging due to both 
mechanisms (DNA damage and telomere shortening) is strongly dependent on p53 status. These 
two mechanisms can also act cooperatively to increase the overall level of genomic instability, 
triggering the onset of human aging phenotypes.
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Introduction
Aging is an extremely complicated process and is known to be driven by a variety 
of different mutually interacting mechanisms. Conventionally, it is seen as a process 
of progressive failure of homeostasis involving genes for maintenance and repair, 
environmental factors leading to molecular damage and molecular heterogeneity, 
and chance events with potentially signiﬁ  cant consequences for death (Alberts et al 
2002). Since several human progeroid synqdromes (PSs) (human premature aging-like 
syndromes) are characterized by features resembling precocious aging, the identiﬁ  ca-
tion of the genes involved in PSs has provided important clues to understanding the 
molecular mechanisms underlying normal human aging (Hutchinson 1886, Gilford 
1904; Martin 1978, 1985).
The classic example of PS is Werner’s syndrome (WS), a progeria of the adult, 
which is caused by a mutation in a gene coding for a member of the RecQ helicase 
family, WRN (Yu et al 1996) and is characterized by features resembling preco-
cious aging, appearing as a variety of visible features associated with aging, such 
as graying of the hair and skeletal changes, which occur much earlier than normal 
(Goto 1997). WRN acts as a “caretaker of the genome” and functions in both DNA 
repair and transcription, suggesting that breakdown of these processes is critical in 
promoting aging (Epstein et al 1966; Goto 1997; Bachrati et al 2003). Hutchinson-
Gilford progeria syndrome (HGPS), a progeria of the child, is the other classic 
example, and is caused by mutations in the gene LMNA (1q21.2) (Eriksson et al 
2003), encoding a nuclear envelope protein, lamin A, which has been shown to affect 
RNA polymerase II transcription, probably by alterations in chromatin organization Clinical Interventions in Aging 2008:3(3) 432
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(Martin and Oshima 2000; Spann et al 2002; Hickson 
2003; Andressoo and Hoeijmakers 2005). In addition, 
skin ﬁ  broblast biopsies from patients with HGPS fail to 
show evidence of normal DNA strand rejoining in vitro 
after exposure to irradiation, suggesting that DNA repair 
may be absent or greatly reduced in the cells (Epstein et al 
1973). Thus, these two PSs directly mimic the clinical 
and molecular features of natural aging, providing unique 
insights into the molecular mechanisms underlying human 
aging (Martin 1978, 1985). In this review, we will focus on 
these two best characterized PSs, with particular emphasis 
on the functions of the mutated syndrome-causing genes, 
and their potential implications for resemble aging. Based 
on the current information on these two syndromes, we also 
propose a model to explain human aging.
Werner’s syndrome
Werner’s syndrome is a rare autosomal recessive disorder 
characterized by premature aging (Epstein et al 1966; 
Martin et al 1970; Goto et al 1996; Yu et al 1996). The 
WRN gene responsible for WS encodes the 1432 amino 
acid WRN protein, which is a member of the RecQ DNA 
helicase family (Yu et al 1996). The C-terminal region of 
WRN contains the conserved RQC domain, which includes 
a nucleolar targeting sequence (NTS) (Marciniak et al 1998; 
von Kobbe and Bohr 2002), and the helicase and RNaseD 
C-terminal (HRDC) domain (Liu et al 1999). WRN has 
DNA-dependent ATPase, DNA strand annealing, DNA 
helicase, and exonuclease activities (Gray et al 1997; 
Suzuki et al 1997, 1999; Huang et al 1998). WRN, as a 
“caretaker of the genome”, is needed to prevent telomere 
dysfunction and consequent genomic instability (Opresko 
et al 2003; Crabbe et al 2004; Du et al 2004). Since most of 
the mutations identiﬁ  ed in WRN cause premature termina-
tion of translation (Goto 1997; Yu et al 1997), resulting in 
impaired nuclear import of the protein (Matsumoto et al 
1997), the clinical features and cellular phenotypes of WS 
patients are major due to an absolute lack of normal WRN 
in the nucleus. WS cells have defects in DNA replication, 
resulting in dysfunction in multiple cellular DNA metabolic 
processes, such as DNA replication initiation, replication 
foci establishment, and the resolution of stalled replication 
forks during replication and DNA repair (Martin et al 1970; 
Hasty et al 2003). In addition, a large number of reports 
have shown that many cellular events, including transcrip-
tion and apoptosis, are affected in WS cells (Ogburn et al 
1997; Balajee et al 1999; Spillare et al 1999, 2006; Som-
mers et al 2005). The loss of WRN function in WS appears 
as chromosome instability, a shorter life span in culture 
(Martin 1977), and accelerated telomere shortening (Schulz 
et al 1996), suggesting that breakdown of WRN function 
is important in promoting aging (Martin et al 1970; Hasty 
et al 2003).
Multiple functions of the WRN 
protein
Biochemistry and catalytic activities
WRN, a multifunctional nuclear protein, interacts with a 
number of proteins to catalyze four major DNA-dependent 
enzymatic activities, acting (1) as a DNA-dependent ATPase, 
(2) as an intrinsic 3′→5′ helicase (Gray et al 1997), (3) as a 
3′→5′ exonuclease (Huang et al 1998, 2000), and (4) in 
DNA strand annealing (Machwe et al 2005), and interacts 
with factors with established roles in DNA metabolic path-
ways (Brosh and Bohr 2002). WRN contains three distinct 
structure-speciﬁ  c DNA-binding domains, one N-terminal 
domain and two different C-terminal fragments (the 
RecQ and HRDC domains), each of which plays roles 
in distinct DNA metabolic pathways (von Kobbe et al 
2003a).
ATP-stimulated activities are required for the suc-
cessive steps in the hydrolytic reaction, such as structure 
recognition, DNA binding, and 3′-terminal hydrolysis. In 
this context, WRN plays a DNA-dependent ATPase, using 
the energy from ATP hydrolysis to unwind double-stranded 
DNA, and its exonuclease and helicase activities act in con-
cert to catalyze structure-dependent DNA degradation in 
resolving aberrant DNA structures (Shen and Loeb 2000). 
As a helicase, WRN is active on the forked end of a DNA 
duplex, while, as an exonuclease, it acts on the blunt end 
of the same duplex (Gray et al 1997; Huang et al 1998; 
Opresko et al 2001). WRN exonuclease can efﬁ  ciently 
remove a mismatched nucleotide at a 3′ recessed terminus 
and can initiate DNA degradation from a 12-nucleotide 
gap or a nick (Huang et al 2000). Furthermore, WRN 
forms a trimer, which interacts with the proliferating cell 
nuclear antigen (PCNA) to participate in the replication 
restart process (Huang et al 2000; Rodríguez-López et al 
2003; Jeziorny et al 2006). WRN exonuclease activity is 
suppressed by interaction with p53 (Brosh et al 2001a) or 
BLM (von Kobbe et al 2002) and stimulated by interaction 
with Ku70/80 (Li and Comai 2001) or phosphorylation 
(Karmakar et al 2002). WRN helicase activity is stimulated 
by interaction with replication protein A (RPA) (Shen et al 
1998) or telomere repeat binding factor 2 (TRF2) (Opresko 
et al 2002) and phosphorylation (Karmakar et al 2002). Clinical Interventions in Aging 2008:3(3) 433
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Moreover, WRN colocalizes and interacts with RAD52 
and has strand annealing activity in addition to its DNA 
unwinding activity (Baynton et al 2003; Machwe et al 
2005, 2006). WRN-dependent unwinding activity is 
signiﬁ  cantly stronger than previously believed (Machwe 
et al 2006).
Post-translational modiﬁ  cations
In response to DNA damage, WRN can be modulated by 
post-translational modiﬁ  cations, including phosphoryla-
tion, sumoylation, and acetylation. It is phosphorylated 
at serine/threonine and tyrosine residues in vivo after 
bleomycin treatment or after replication stress (Karmakar 
et al 2002; Cheng et al 2003; Pichierri et al 2003). WRN 
phosphorylation at serine/threonine residues is primarily 
dependent on DNA-PKcs and c-Abl kinases (Karmakar 
et al 2002; Cheng et al 2003; Pichierri et al 2003). Impor-
tantly, the serine/threonine phosphorylation of WRN by 
the DNA-PK complex results in inhibition of both WRN 
helicase and exonuclease activities, whereas dephosphory-
lation of WRN enhances both these activities. Thus, the 
serine/threonine phosphorylation status of WRN plays a 
role in the regulation of its catalytic activities (Karmakar 
et al 2002; Cheng et al 2003). c-Abl was also found to 
phosphorylate WRN (Cheng et al 2003). c-Abl kinase, a 
regulator of the DNA damage response, mediates WRN 
nuclear localization and catalytic activities in response 
to DNA damage. WRN directly binds to c-Abl and this 
interaction is disrupted in the early cellular response to 
bleomycin (Cheng et al 2003). As with phosphorylation 
by the DNA-PK complex, c-Abl phosphorylation inhibits 
WRN helicase and exonuclease activities (Cheng et al 
2003).
Phosphorylation of WRN may inﬂ  uence other forms of 
WRN post-translational modiﬁ  cation, such as sumoylation 
and/or acetylation. Modiﬁ  cation of proteins by the small 
ubiquitin-related modiﬁ  er 1 (SUMO-1) conjugating system 
requires a set of enzymes, including SUMO-activating 
(E1), conjugating (Ubc9), and ligating enzymes (Muller 
et al 2004). WRN interacts with Ubc9, which is required 
for conjugation of SUMO-1 to the N-terminal fragment 
(amino acids 272–514) of WRN (Kawabe et al 2000). In 
addition, binding of p14 Arf to WRN is multivalent and 
resembles the binding of p14 Arf to Mdm2, promoting 
sumoylation of WRN in a synergistic manner with the 
SUMO-conjugating enzyme Ubc9 (Woods et al 2004). p14 
Arf causes redistribution of WRN within the nucleus, and 
this effect is reversed by expression of a SUMO-speciﬁ  c 
protease, thus implicating the SUMO conjugation pathway 
in controlling WRN re-localization (Woods et al 2004). 
Besides phosphorylation and sumoylation, WRN can be 
acetylated after mitomycin C or methyl methane-sulfonate 
treatment (Sharma et al 2005). On exposure to UV or 
ionizing radiation, WRN is acetylated by acetyltransferase 
p300, a transcriptional coactivator, which has acetylation 
activity (Blander et al 2002).
DNA replication
WRN helicase unwinds replication fork structures very 
efﬁ  ciently (Mohaghegh et al 2001), acting to resolve the 
block and/or in the replication restart process (Rodríguez-
López et al 2003). Compared to normal cells, cells from WS 
patients undergo premature replicative senescence (Martin 
et al 1970; Salk et al 1985), display an extended S-phase 
(Poot et al 1992), and show a reduced frequency of replication 
initiation sites (Takeuchi et al 1982; Hanaoka et al 1985), 
thus exhibiting defects in DNA replication consistent with 
the inability to properly recover from DNA replication fork 
demise (Hickson 2003).
WRN is able to interact with PCNA, DNA topoisomer-
ase I (topo I), polδ, and RPA (Wold 1997; Lebel and Leder 
1998; Brosh et al 1999; Lebel et al 1999; Constantinou et al 
2000; Huang et al 2000; Laine et al 2003) and catalyze DNA 
unwinding in vitro for DNA replication, recombination, and 
repair (Brosh and Bohr 2002).
WRN and PCNA colocalize at replication foci, suggesting 
a physiological interaction between them in cycling primary 
cells (Rodríguez-López et al 2003). In addition, WRN is as 
part of the 17S multiprotein DNA replication complex, and 
establishes PCNA and topoisomerase I as the two WRN-
interacting components (Warbrick 1998, 2000; Lebel et al 
1999; Rodríguez-López et al 2003).
Polδ participates in DNA replication and repair of DNA 
damage. WRN interacts speciﬁ  cally with the p50 subunit of 
polδ, and WRN directly modiﬁ  es DNA replication via its 
interaction with p50 and is involved in the dynamic relocal-
ization of polδ complexes within the nucleus (Kamath-Loeb 
et al 2000; Szekely et al 2000). Moreover, WRN enhances the 
rate of nucleotide incorporation in polδ-mediated replication 
in the absence of PCNA and its helicase activity enables polδ 
to overcome hairpin and G-quadruplex DNA structures (Fry 
and Loeb 1999; Szekely et al 2000; Kamath-Loeb et al 2000, 
2001; Brosh et al 2001b; Mohaghegh et al 2001). Thus, WRN 
may facilitate polδ-mediated DNA replication, and disruption 
of the WRN-polδ interaction in WS cells may contribute to 
the S-phase defects.Clinical Interventions in Aging 2008:3(3) 434
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Human RPA is a heterotrimeric, single stranded DNA-
binding protein required for DNA replication, recombina-
tion, and repair (Wold 1997; Brosh et al 1999, 2002). RPA 
directly interacts with to WRN, markedly increasing the 
DNA helicase activity of WRN (Brosh et al 1999; Shen 
et al 2003) and its ability to unwind forked telomeric DNA 
structures (Ohsugi et al 2000; Opresko et al 2001). After 
DNA damage, WRN can colocalize with BLM and RPA 
(Constantinou et al 2000; Bischof et al 2001; Sakamoto 
et al 2001). RPA binds to WRN and BLM to stimulate their 
unwinding of long DNA duplexes (Bachrati and Hickson 
2003).
Another interesting replication protein, FEN-1, interacts 
with the 144-amino acid RQC domain on the C-terminal 
region of WRN (Brosh et al 2001c). FEN-1, a DNA 
structure-speciﬁ  c nuclease, participates in pathways of 
DNA metabolism that are important for genomic stability 
(Brosh et al 2002) and is involved in the maturation of 
Okazaki fragments during lagging strand DNA replication 
(Bambara et al 1997; Merrill and Holm 1998). WRN 
stimulates FEN-1-mediated cleavage activity of displaced 
ﬂ  aps that occur during lagging strand DNA synthesis at 
Okazaki fragments (Brosh et al 2001c; Sharma et al 2004). 
WRN-FEN-1 complex colocalizes in foci associated with 
arrested replication forks, and this complex plays a role in 
the unwinding and degradation of Holliday junction struc-
tures associated with regressed replication forks (Sharma 
et al 2004). Defective Okazaki fragment processing causes 
DSBs, which may lead to the genomic instability in WS 
(Brosh et al 2002).
WRN colocalizes with, and directly interacts with, human 
topo I (Laine et al 2003). WRN stimulates the ability of 
topo I to relax negatively supercoiled DNA and speciﬁ  cally 
stimulates the religation step of the relaxation reaction, and 
cell extracts from WS ﬁ  broblasts exhibit a decreased ability 
to unwind negatively supercoiled DNA (Laine et al 2003). 
These ﬁ  ndings provide the interrelationship between WRN 
helicases and topoisomerases in the maintenance of genomic 
integrity.
DNA repair
WS cells display sensitivity to 4-nitroquinoline 1-oxide 
(Ogburn et al 1997; Poot et al 2002), a carcinogen which 
causes the formation of DNA strand breaks and bulky DNA 
adducts (Nagao and Sugimura 1976), and are also hypersen-
sitive to O6-methylguanine, a site-speciﬁ  c alkylating agent 
that can block DNA replication (Blank et al 2004). WS cells 
are sensitive to DNA crosslinking drugs (Poot et al 2001, 
2002) and, since DNA crosslinks are normally repaired by 
homologous repair (HR), this suggests a defect in this repair 
pathway. WS cells display extensive deletions at nonhomolo-
gous joined ends (Oshima et al 2002; Chen et al 2003), while 
expression of wild-type WRN prevents excessive DNA dele-
tions (Oshima et al 2002; Chen et al 2003). These ﬁ  ndings 
suggest that lack of WRN may increase DNA damage and 
disrupt the regulatory processes controlling DNA repair, for 
example, nonhomologous end joining (NHEJ), HR, and base 
excision repair (BER).
Double-strand break repair
The ﬁ  rst evidence for a link between WRN and double-strand 
break repair was the discovery that WRN interacts with both 
Ku and DNA-dependent protein kinase catalytic subunits 
(DNA-PKcs) (Cooper et al 2000; Li and Comai 2000; Cheng 
et al 2003; Opresko et al 2003) to participate in NHEJ (Li and 
Comai 2002). Assembly of DNA-PK and WRN at DNA ends 
allows DNA-PKcs to phosphorylate WRN, thus stimulating 
WRN enzymatic activity and facilitating efﬁ  cient processing 
of double-strand breaks (DSBs) prior to ligation (Yannone 
et al 2001). Deﬁ  ciencies in either Ku or DNA-PKcs result 
in sensitivity to ionizing radiation due to defects in DSB 
repair. Complementation with the exonuclease/helicase 
double mutant or wild-type WRN restores NHEJ activity, 
suggesting that WRN is necessary for normal repair of DSBs 
(Chen et al 2003).
Chromatographic studies showed that WRN is bound 
to PARP-1 in a complex that contains Ku70/80 (Li et al 
2004). PARP-1 can induce apoptosis or necrosis in cells 
with extensive DNA damage. Absence of functional WRN 
prevents activation of PARP-1 in response to DNA damage 
caused by oxidative stress and alkylating agents (von Kobbe 
et al 2003b).
Some proteins that participate in the recombinational 
repair pathway have been found to functionally interact 
with WRN. WRN is involved in resolving recombination 
intermediates in RAD51-dependent HR (Prince et al 2001; 
Saintigny et al 2002) and forms distinct nuclear foci that 
partially overlap with the RAD51 nuclear foci formed in 
response to DNA damage (including DSBs) (Sakamoto 
et al 2001). In vivo data show that WRN interacts function-
ally with NBS1 (Cheng et al 2004), which is thought to act 
downstream of RAD51 (Saintigny et al 2002; Tauchi et al 
2002; Monnat and Saintigny 2004). WRN colocalizes with, 
and interacts with, RAD52 (Baynton et al 2003), NBS1 in 
the MRN complex (Cheng et al 2004), and ﬂ  ap endonuclease 1 
(FEN-1) (Brosh et al 2001c; Sharma et al 2004). In addition, it Clinical Interventions in Aging 2008:3(3) 435
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interacts physically with the Mre11-RAD50-NBS1 complex, 
which also functions in HR for DSB processing (Cheng et al 
2004).
Base excision repair
Oxidative DNA lesions are repaired primarily by base 
excision repair (BER), and the accumulation of oxidative 
products and the resulting phenotypic changes have been 
implicated in the aging process (Beckman et al 1998). In 
general, BER can be divided into short patch repair and long 
patch repair. WRN has been shown to physically interacts 
with polβ and participate in short patch BER (Harrigan 
et al 2003). The active WRN helicase domain stimulates 
polβ strand displacement DNA synthesis at a nick on a 
BER substrate (Harrigan et al 2003). In addition, it has been 
shown to interact physically and/or functionally with several 
replication proteins which participate in long patch BER, 
including PCNA, RPA, polδ, and FEN-1 (Shen et al 1998; 
Brosh et al 1999, 2002; Kamath-Loeb et al 2001). PCNA is 
part of a sliding clamp which forms a ring which maintains 
the connection between polymerase and its DNA template, 
allowing uninterrupted synthesis. WRN has been shown to 
directly interact with PCNA in vitro, suggesting a unique 
role for WRN in DNA synthesis (Huang et al 2000). WRN 
stimulates FEN-1 ﬂ  ap cleavage (Brosh et al 2001c, 2002) 
and nucleotide incorporation by polδ (Kamath-Loeb et al 
2000, 2001). RPA stimulates WRN helicase unwinding of 
long substrates (Shen et al 1998; Brosh et al 1999) and the 
poly(ADP-ribosyl)ation state of PARP-1 regulates WRN 
helicase and exonuclease activities (von Kobbe et al 2004). 
PARP-1 binds strongly to strand breaks and acts in the DNA 
damage surveillance network, partly by ribosylating a variety 
of nuclear proteins in response to DNA damage.
DNA recombination
Cellular DNA recombination can occur physiologically 
during meiotic DNA replication and V(D)J recombination, 
or can be induced by DNA damaging agents. Some reports 
define a physiological role for WRN RecQ helicase in 
recombination via RAD51-dependent HR (Prince et al 2001; 
Saintigny et al 2002). WRN and BLM colocalize to DNA 
damage-induced RAD51 foci, implicated in HR (Bischof 
et al 2001; Sakamoto et al 2001; Wu et al 2001; Saintigny 
et al 2002; Von Kobbe et al 2002; Wu and Hickson 2003; 
Spillare et al 2006). The WRN and BLM helicase activities 
are possible in a synergistic manner to intermediate DNA 
recombination, since a coimmunoprecipitation and colocal-
ization study showed that the exonuclease domain of WRN 
interacts with BLM (von Kobbe and Bohr 2002). In addition, 
a biochemical study showed that WRN interacts with the 
homologous recombination mediator protein RAD52, and 
that WRN and RAD52 form a complex, should be a gen-
eral response to replication forks arrested by DNA damage 
(Baynton et al 2003).
WRN interacts physically and functionally with the MRN 
complex via NBS1 and they colocalize in response to ionizing 
radiation or mitomycin C treatment (Cheng et al 2004). WS 
cells display a deﬁ  ciency in resolving DNA recombination 
intermediates which contributes to DNA damage hypersen-
sitivity, limited cell growth, and genomic instability (Prince 
et al 2001). The generation of viable mitotic recombinant 
progeny was rescued by the expression of WRN, which also 
improved WS cell survival after DNA damage (Saintigny 
et al 2002). These results deﬁ  ne a physiological role for the 
WRN RecQ helicase protein in RAD51-dependent HR and 
identify a mechanistic link between defective recombina-
tion resolution and limited cell division potential, DNA 
damage hypersensitivity, and genetic instability in human 
somatic cells (Saintigny et al 2002). WRN also colocal-
izes with RAD51 and RPA in response to DNA damaging 
agents (Constantinou et al 2000; Sakamoto et al 2001), and 
both WRN and BLM interact with RPA (Brosh et al 1999, 
2000).
Telomere maintenance
Telomeres are specialized nucleoprotein structures con-
sisting of G-rich repetitive sequences that cap the ends of 
eukaryotic chromosomes and are crucial for the maintenance 
of chromosomal integrity and cell viability (McClintock et al 
1941). They are maintained by the enzyme telomerase, which 
consists of an essential telomerase RNA component (TERC), 
which serves as a template for the addition of telomere 
repeats, and a protein component, the telomerase reverse 
transcriptase catalytic subunit (TERT). Telomere shorten-
ing eventually results in diverse pathophysiological conse-
quences, primarily through accelerated telomere erosion, and 
triggers entry into premature senescence (Wright and Shay 
1992; Blasco 2002; Chang et al 2004; Du et al 2004). Defects 
in telomere structure can initiate a DNA damage response and 
may lead to telomeric end fusions and chromosome breakage 
if not properly repaired (De Lange 2002).
Biochemical and cellular evidence suggest that WRN 
may dissociate secondary structures at the telomere to allow 
replication, repair, and telomerase activity at the telomere 
end (Opresko et al 2003). Under normal conditions, WRN 
associates with telomeres in S phase to prevent loss of Clinical Interventions in Aging 2008:3(3) 436
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individual telomeres (Crabbe et al 2004). Accelerated loss 
of telomere reserves and activation of cellular checkpoints 
appear integral to the decreased replicative potential seen 
in WS, as evidenced by the capacity of enforced TERT 
expression to impart unlimited replicative potential (Wyllie 
et al 2000).
WRN functionally interacts with a number of proteins 
involved in telomere length maintenance, including Ku 
70/86 (Orren et al 2001), RPA (Brosh et al 1999, 2000; Sanz 
et al 2000), TRF1, and TRF2 (Opresko et al 2002, 2004; 
Machwe et al 2004). RPA is a single strand DNA-binding 
protein that is required for all aspects of DNA metabolism 
(Brosh et al 2000), while TRF1 and TRF2 are homodimeric 
proteins that have been shown to bind exclusively to double 
stranded telomeric DNA throughout the cell cycle and are 
thought to be involved in the regulation of telomeric length 
(Fairall et al 2001). TRF2 as a promoter for the helicase 
activity of WRN, the interaction between WRN and TRF2 
may serve to stabilize TRF2 in its active form or to improve 
TRF2’s interaction with DNA (Opresko et al 2002). Due 
to the absence of WRN in WS patients, TRF2 is unable to 
perform its duty and telomeric-speciﬁ  c structures that need to 
be degraded are not (Grifﬁ  th 1999; Opresko 2002; Jeziorny 
2006). These structures then act as barriers against various 
transcription factors and telomeres are left without being 
fully transcribed.
Taken together, these results suggest that WRN is 
necessary for the efﬁ  cient replication of G-rich telomeric 
DNA and that WRN deﬁ  ciency and dysfunctional telomeres 
appear to act cooperatively to increase the overall level 
of genomic instability, triggering the onset of premature 
aging phenotypes (Orren et al 2001; Opresko et al 2002, 
2004).
DNA apoptosis
A link between WRN and apoptosis was ﬁ  rst proposed by 
studies demonstrating that WS ﬁ  broblasts exhibit a decreased 
p53- mediated apoptotic response, and this deﬁ  ciency can be 
rescued by expression of wild-type WRN (Spillare et al 1999). 
p53 is a key cellular component in maintaining genomic 
stability either by regulating the cell cycle to allow DNA 
repair or by inducing apoptosis (Haupt et al 2003; Hofseth 
et al 2004; Lane 2004). The C-terminus of WRN binds to the 
C-terminal domain of p53 to induce p53-mediated apoptosis 
(Clarke et al 1993; Symonds et al 1994; Wang et al 1996, 
2001; Spillare et al 1999; Brosh et al 2001a).
Fibroblasts from WS patients have a decreased ability 
to undergo p53-mediated apoptosis (Spillare et al 1999), so 
the absence of WRN-p53 direct interaction could serve as a 
signal for programmed cell death. Moreover, the expression 
of wild-type WRN is sufﬁ  cient to rescue WS¯/¯ cells from the 
attenuation of p53-mediated apoptosis (Spillare et al 1999; 
Blander et al 2001). p53 may exert its effect on WRN by its 
interaction with RPA. Overexpression of p53 results in a 
decrease in Sp-1-mediated transcription of the WRN gene, 
suggesting that p53 regulates WRN expression (Yamabe et al 
1998). Thus, the interaction of WRN with p53 and/or the 
WRN-RPA complex may be critical in preventing entry into 
S phase or in directing S phase cells towards apoptosis. The 
absence of a p53-WRN helicase interaction may disrupt the 
signal to direct S-phase cells into apoptosis for programmed 
cell death and contribute to the pronounced genomic insta-
bility and cancer predisposition seen in WS cells (Sommers 
et al 2005). In addition, epigenetic inactivation (promoter 
hypermethylation) of WRN can lead to the loss of WRN-
associated exonuclease activity and increased chromosomal 
instability and apoptosis induced by topoisomerase inhibitors 
(Agrelo et al 2006).
Hutchinson-Gilford progeria 
syndrome
Hutchinson-Gilford progeria syndrome, a childhood 
progeroid disorder, is a rare, fatal genetic disorder charac-
terized by segmental accelerated aging. Affected children 
appear normal at birth, but within a year develop character-
istic features of failure to thrive, delayed dentition, alopecia, 
atherosclerosis, prominent scalp veins, a high pitched voice, 
and sclerodermatous skin changes, with death at approxi-
mately 13 years from atherosclerosis of the coronary and 
cerebrovascular arteries. Eriksson and colleagues (2003) 
identiﬁ  ed the disease causing mutations in the LMNA gene 
(encoding lamin A/C). The vast majority of HGPS cases 
are caused by a single-base substitution (GGC  GGT), 
which does not cause an amino acid change (G608G), but 
results in deletion of 150 nucleotides in exon 11, causing 
an alternatively spliced truncated variant of lamin A mRNA 
and an in-frame deletion of 50 amino acids near the carboxy 
terminus, leading to changes in the nuclear architecture (De 
Sandre-Giovannoli et al 2003; Eriksson et al 2003). Other 
HGPS mutations that have been described in LMNA include 
E145K, R471C, R527C, G608S, T623S, and 1824C  T 
(Cao and Hegele 2003; Csoka et al 2004a; Fukuchi et al 
2004). Lamins form microﬁ  laments in the nucleus and are 
important in maintaining the proper structure of the nuclei, 
but they also inﬂ  uence on chromatin structure, regula-
tion of gene expression, localization and probably protein Clinical Interventions in Aging 2008:3(3) 437
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degradation (Ly et al 2000; Goldman et al 2002; Scafﬁ  di 
and Misteli 2005). Immunoﬂ  uorescence of HGPS ﬁ  bro-
blasts with antibodies directed against lamin A revealed 
that many cells show visible abnormalities of the nuclear 
membrane (Eriksson et al 2003). In addition, HGPS cells 
have also altered histone modiﬁ  cation patterns, including 
reduced heterochromatin-speciﬁ  c trimethylation of Lys9 
on histone H3 (Tri-Me-K9H3) (Scafﬁ  di and Misteli 2005, 
2006). A recent study implicated lamin A in physiological 
aging, showing that the molecular mechanism responsible 
for the premature aging (Hasty and Vijg 2004; Scafﬁ  di and 
Misteli 2006). Thus, accelerated aging in HGPS might thus 
reﬂ  ect an exaggerated lamin A-dependent mechanism, which 
contributes to physiological aging.
Defects in prelamin A processing
Lamin A has a conserved C-terminal CAAX motif, which 
is a potential target for subsequent processing steps. To 
generate mature lamin A, prelamin A undergoes substantial 
post-translational modiﬁ  cation of its CAAX motif via four 
processing steps (Zhang and Casey 1996; Young et al 2006). 
First, a 15-carbon farnesyl lipid is added to the thiol group 
of the cysteine by a cytosolic enzyme, protein farnesyltrans-
ferase. Second, the last three amino acids of the protein 
(ie, the -AAX) are clipped off by the metalloprotease ZMP-
STE24 and/or RCE1 (Bergo et al 2002; Corrigan et al 2005). 
Third, the newly exposed farnesylcysteine is carboxylmethyl-
ated by ICMT, a prenylprotein-speciﬁ  c methyltransferase in 
the endoplasmic reticulum (Clarke et al 1988; Dai et al 1998). 
Fourth, the last 15 amino acids of the protein, including the 
farnesylcysteine methyl ester, are clipped off by ZMPSTE24 
and degraded, releasing mature lamin A (Weber et al 1989; 
Beck et al 1990; Corrigan et al 2005; Young et al 2006). In 
HGPS, a 50-amino acid deletion in the C-terminus of the pro-
tein (amino acids 607–656) lacks an important endoprotease 
cleavage site recognized by ZMPSTE24 during prelamin A 
post-translational processing, so no mature lamin A is formed 
and a farnesylated mutant prelamin A (progerin) accumulates 
in cells (De Sandre-Giovannoli et al 2003; Eriksson et al 
2003; Navarro et al 2006; Sun and Schatten 2006; Tsai et al 
2006; Young et al 2006).
Progerin accumulation and nuclear 
morphology abnormalities
The mutant prelamin A is targeted to the nuclear rim, where 
it disrupts the integrity of the nuclear lamina, leading to 
premature cell death (Eriksson et al 2003; Goldman et al 
2004; Varela et al 2005; Yang et al 2005; Fong et al 2006). 
The GGC  GGT (G608G) mutation of LMNA causes 
accumulation of farnesyl-prelamin A in the nucleus in a cel-
lular age-dependent manner, and the cells display irregular 
nuclear shapes, including lobulation of the nuclear envelope, 
thickening of the nuclear lamina, loss of peripheral hetero-
chromatin, and clustering of nuclear pores (Eriksson et al 
2003; Goldman et al 2004). Aberrant nuclear morphology is 
also reported with other LMNA mutations, which have been 
linked to other ‘‘laminopathies’’, such as Emery–Dreifuss 
muscular dystrophy, dilated cardiomyopathy-1A, Dun-
nigan-type familial partial lipodystrophy, mandibuloacral 
dysplasia, and atypical WS (Goldman et al 2002; Chen 
et al 2003). In HGPS cells, the nuclei and lamina appeared 
normal at early passages, but, at later passages, the nuclei 
are severely misshapen and contain an abnormally thick 
lamina (de Sandre-Giovannoli et al 2003; Eriksson et al 
2003). These structural defects worsen as HGPS cells age in 
culture, and their severity correlates with an obvious increase 
in mutant lamin A (Goldman et al 2004). An abnormal 
distribution of nuclear pore complexes is seen in late pas-
sage HGPS cells. The changes in nuclear pore complexes 
gradually affect various aspects of the normal trafﬁ  cking of 
protein and RNA across the nuclear envelope, having severe 
effects on the physiological state of HGPS cells (Yoshida 
and Blobel 2001). In addition, mutant lamin A induces 
decreased cellular proliferation, premature senescence, and 
altered motility (Goldman et al 2004). The highly lobulated 
late passage HGPS cells primarily exhibit PCNA patterns 
resembling early S phase, suggesting that there is a block 
in the transition from the early chain-elongation phase of 
DNA replication to the mid- and later phases of replication. 
Mutant lamin A (progerin) progressively accumulates in the 
nucleus with cellular age, resulting in premature cessation 
of growth in the later passages of HGPS cells (Goldman 
et al 2004).
Universal transcriptional alterations
Lamin A is a major constituent of the nuclear membrane, 
and an immunoﬂ  uorescence study of HGPS ﬁ  broblast nuclei 
demonstrated abnormalities (Goldman et al 2004). Given 
the prominent structural role of lamin A in the nuclear 
membrane, it is suggested that this protein has diverse 
roles in DNA metabolism, including DNA replication and 
transcription. Gene expression in HGPS was investigated by 
measuring mRNA levels in ﬁ  broblasts isolated from young, 
middle aged, and old humans with or without progeria 
(Ly et al 2000). Of the 152 genes studied, 47 (31%) were 
differentially transcribed in both old and HGPS compared Clinical Interventions in Aging 2008:3(3) 438
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to young. The direction of the change was the same in 
old and HGPS for all coregulated genes. Genes involved 
in mitosis were downregulated and the observed changes 
might result in increased rates of somatic mutation, leading 
to chromosome aberrations and mutations manifesting as 
an aging phenotype. Csoka and colleagues (2004b) found 
that the genes differentially expressed in HGPS ﬁ  broblasts 
compared to age-matched control cell lines are involved 
in a variety of biological processes. Of the approximately 
33,000 genes analyzed, 361 (1.1%) showed at least a 2 fold 
change in HGPS compared to the aged controls. The most 
prominent categories encoded transcription factors and 
extracellular matrix proteins, many of which are known to 
function in the tissues severely affected in HGPS. The most 
affected gene was MEOX/GAX, a homeobox gene that func-
tions as a negative regulator of proliferation. Several genes 
involved in DNA replication and chromatin remodeling were 
downregulated. These changes were interpreted as contrib-
uting to depression of cellular proliferation. Some of the 
transcription changes suggested excess extracellular matrix 
deposition through the increased expression of extracellular 
matrix components and decreased expression of extracellular 
matrix remodeling enzymes. Of the 58 genes examined by 
both of these groups, the expression of 17 (29%) changed in 
the same direction, demonstrating a reasonable agreement 
between the two studies considering their different designs. 
The studies by Kyng and Bohr (2005) and Csoka and col-
leagues (2004b) point to a shared mechanism of aging accel-
eration in PSs ie, misregulated transcription. The idea that 
aging is due to the loss of the proper transcriptional state of 
the cell followed by “dysdifferentiation” had been previously 
proposed by other investigators (Kator et al 1985; Zs-Nagy 
et al 1988; Fossel 2003; Prolla 2005). These ﬁ  ndings that 
HGPS patients show inappropriate transcriptional patterns 
provides new evidence that transcriptional deregulation can 
contribute to the aging process in humans.
Genomic instability
DNA damage accumulation and the effects of repair 
defects can lead to genomic instability associated with 
premature aging and have causal roles in normal aging 
(Lombard et al 2005; von Zglinicki et al 2005). Indeed, 
defective recruitment of 53BP1 and RAD51 to sites of DNA 
lesion is seen in HGPS ﬁ  broblasts, resulting in a delayed 
checkpoint response and defective DNA repair (Liu et al 
2005). Wild-type mouse embryonic ﬁ  broblasts ectopically 
expressing unprocessible prelamin A show similar defects 
in checkpoint response and DNA repair (Liu et al 2005). 
These results indicate that unprocessed prelamin A and 
truncated lamin A act dominant negatively to perturb the 
DNA damage response and repair, resulting in genomic 
instability, which might contribute to laminopathy-based 
premature aging (Liu et al 2005). In HGPS cells, DNA dam-
age checkpoints are persistently activated, and inactivation 
of checkpoint kinases ATM and ATR can partially restore 
cell cycle progression into S-phase (Cortez et al 2001; Liu 
et al 2006), suggesting that senescence can be suppressed 
by inactivating DNA damage response pathways in HGPS 
cells. Organismal aging has been linked to activation of 
p53-dependent signaling pathways and initiation of the 
senescence program in a premature aging mouse model 
(Varela et al 2005). Inhibition of aberrant splicing of lamin 
A results in signiﬁ  cant downregulation of p21, IGFBP3, and 
GADD45B compared with mock-treated cells (Scafﬁ  di and 
Misteli 2006). Consistent with the reduction in p53 activa-
tion, upon elimination of Δ50 lamin A from old cells, the 
fraction of 5-bromo-2’-deoxyuridine-positive proliferating 
cells increased by 30% and was similar to that in mock-
treated young cells. Over the past few years, there have 
been reports that progerin leads to defective DNA repair 
and genome instability (Liu et al 2005), overexpression of 
p53 target genes (Varela et al 2005), and changes in his-
tone methylation that affect heterochromatin organization 
(Shumaker et al 2006).
Farnesyltransferase inhibitor
Farnesyl-prelamin A is targeted to the nuclear envelope, 
where it interferes with the integrity of the nuclear enve-
lope and causes misshapen cell nuclei. It has also been 
shown to affect the mechanical stability of the nucleus 
(Dahl et al 2006). Farnesyltransferase inhibitors (FTIs) 
can block prelamin A processing and reduce the percent-
age of cells with misshapen nuclei (Capell et al 2005; 
Glynn and Glover 2005; Mallampalli et al 2005; Toth et al 
2005). Thus, the favorable effects of FTIs raise the ques-
tion whether an FTI might improve disease phenotypes in 
HGPS (Young et al 2006). It is also important to deﬁ  ne the 
extent to which these abnormalities are affected by an FTI 
and to determine whether FTIs will be a useful therapy in 
children with HGPS. A recent study found that treatment 
of patient’s cells with an FTI did not result in a reduction 
in DNA DSBs and damage checkpoint signaling, although 
it signiﬁ  cantly reversed the aberrant shape of their nuclei 
(Liu et al 2006), suggesting that DNA damage accumula-
tion and aberrant nuclear morphology are independent 
phenotypes arising from prelamin A accumulation in these Clinical Interventions in Aging 2008:3(3) 439
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PSs. Yang and colleagues (2006) created gene-targeted mice 
with an HGPS mutation (LmnaHG/+) and examined the 
effect of an FTI on the disease phenotypes. The LmnaHG/+ 
mice exhibited phenotypes similar to those in human HGPS 
patients, including retarded growth, reduced amounts of 
adipose tissue, micrognathia, osteoporosis, and osteolytic 
lesions in bone. In addition, osteolytic lesions in the ribs led 
to spontaneous bone fractures. Treatment with an FTI ame-
liorated the disease phenotypes, resulting in an increased 
adipose tissue mass, improved body weight curves, a reduc-
tion in the number of rib fractures, and improved bone 
mineralization and bone cortical thickness, suggesting that 
FTIs could be useful for treating HGPS patients (Yang et al 
2006). Though FTIs fall short of curing the disease (Yang 
et al 2006), these ﬁ  ndings have established a paradigm for 
ameliorating the most obvious cellular pathology in HGPS 
and suggest a potential strategy for treating this disease.
A hypothetical model of aging
The molecular mechanisms involved in human senescence 
are complicated. Two canonical PSs, WS and HGPS, 
characterized by clinical features mimicking physiologi-
cal aging at an early age, have provided insights into the 
mechanisms of natural aging. In these PSs, several cel-
lular pathways are affected, resulting in the formation of 
endogenous and exogenous sources of oxidative stress, 
telomere attrition, and a decline in DNA repair, which can 
jointly contribute to genomic instability, and subsequently 
result in growth arrest and apoptosis, leading to the human 
aging phenotypes (Karanjawala and Lieber 2004; Prolla 
2005; Collado 2007). The gene defective in WS, WRN, 
encodes a helicase of the RecQ family and possesses 
an exonuclease domain. WRN is involves in multiple 
DNA repair pathways and plays a signiﬁ  cant role in the 
maintenance of overall genomic stability (Bachrati and 
Hickson 2003) (as seen in WS). The clinical features of 
HGPS show similarities to WS, but progress more rapidly 
(Hennekam 2006). LMNA, the gene defective in HGPS, 
affects the structure or post-translational maturation of 
lamin A, a major nuclear component (Eriksson et al 2003). 
Recently, several studies have established a functional 
link between DNA repair and A-type lamin-associated 
syndromes, which are associated with transcriptional 
alterations, abnormal DNA replication, changed organi-
zation of higher order chromatin structure, and genomic 
instability (Serrano and Blasco 2007), suggesting a link 
between these syndromes and physiological aging (as 
seen in HGPS). DNA damage is generated throughout 
life and causes continuous damage to the macromolecular 
components of cells. Importantly, the rate of DNA damage 
production increases with ageing (Hasty and Vijg 2004; 
Serrano and Blasco 2007).
Thus, the causal relationship between the DNA dam-
age response and cellular senescence suggests that DNA 
damage-initiated genomic instability can induce human 
aging phenotypes (Harman 1956). p53-mediated senescence 
and apoptosis in response to DNA damage also probably 
contribute to aging. Indeed, p53, as a master integrator of 
cellular stress, is able to respond to a wide range of DNA 
damage (Horn and Vousden 2007), then, if the stress per-
sists, prevent propagation of the damaged cells (by apop-
tosis or senescence) (Vousden and Lane 2007). Following 
DNA damage, activation of p53 leads to transcription and 
upregulation of p53 target genes, among which P21 acts 
as the major effector of p53-induced cellular senescence. 
P21 levels increase gradually as cells pass into senescence 
(Alcorta et al 1996). Collectively, these results suggest 
that p53 activation is at least partially responsible for the 
induction of cellular senescence in response to DNA dam-
age. On the other hand, various lines of evidence have 
shown that telomere shortening and dysfunction can also 
trigger DNA damage responses and are sufﬁ  cient to induce 
cellular senescence (d’Adda di Fagagna et al 2003; Takai 
et al 2003; Chang et al 2004; Du et al 2004). Some HGP 
ﬁ  broblasts also appear refractory to telomerase-mediated 
immortalization (Wallis et al 2004), and most cultures 
show elevated apoptosis and senescence (Bridger and Kill 
2004). Numerous studies indicate that, in the setting of 
WRN deﬁ  ciency, dysfunctional telomeres trigger the onset 
of premature aging phenotypes, suggesting a link between 
increased telomere dysfunction and the genomic instability 
associated with the aging process (d’Adda di Fagagna et al 
2003; Takai et al 2003; Smogorzewska and de Lange 2004; 
Chang et al 2004; Du et al 2004). On the basis of the infor-
mation available for WS and HGPS, we suggest a model of 
human aging (Figure 1). Human aging can be triggered by 
two main mechanisms, telomere shortening and DNA dam-
age. In telomere-dependent aging, telomere shortening and 
dysfunction can lead to DNA damage responses, inducing 
cellular senescence. In DNA damage-initiated aging, DNA 
damage accumulates, along with DNA repair deﬁ  ciencies, 
resulting in genomic instability and accelerated cellular 
senescence. Both aging mechanisms depend strongly on 
p53 status. These two mechanisms can act cooperatively to 
increase the overall level of genomic instability and trigger 
the onset of human aging phenotypes.Clinical Interventions in Aging 2008:3(3) 440
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